Clin2
NCT06482190Possibly a fitRecruiting

Safety study of an inhaled drug in healthy adults

Idiopathic Pulmonary FibrosisLung; Disease, Interstitial, With Fibrosis

Part of Lungs & breathing clinical trials.

This trial tests the safety of a new inhaled medicine. You must be a healthy nonsmoker, have normal lung function, and agree to avoid certain medications and foods.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
72 people
Ages
18 years to 60 years
Study type
Interventional

Who can take part

  • You must be a healthy volunteer aged 18 to 60.
  • Your weight must be at least 110 pounds (men) or 99 pounds (women), with a body mass index between 18 and 30.
  • You must have normal lung function, including a forced exhale in 1 second (FEV1) of at least 80% of predicted.
  • You cannot smoke, vape, or use nicotine products for 3 months before the study.
  • You must avoid grapefruit, pomelo, alcohol, and caffeine for 48 hours before and during the study.
  • You cannot have any serious medical conditions like heart disease, seizures, or bleeding disorders.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06267183Recruiting· Early Phase 1
Safety study of a new drug in healthy volunteers

This study tests a new investigational drug called SV001 in healthy volunteers to see if it is safe and how the body handles it. It is a first-in-human trial, meaning this drug has not been tested in people before.

Shanghai
NCT07679893Recruiting· Phase 2
Inhaled nintedanib for idiopathic pulmonary fibrosis

This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.

Windsor, Ontario
NCT07600021Not yet recruiting· Phase 2
Testing SYH2059 tablets for idiopathic pulmonary fibrosis

This study tests whether a new tablet called SYH2059 can help slow lung scarring in adults with idiopathic pulmonary fibrosis (IPF), a condition where lung tissue becomes thick and stiff over time. You'll take the study drug alongside your current lung treatment to see if it improves your breathing and lung function.

NCT07687459Not yet recruiting· Phase 3
Study of rentosertib for idiopathic pulmonary fibrosis

This trial tests an oral medicine called rentosertib for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. It aims to see if the drug can help slow the disease. You may qualify if you are 40 or older, have a confirmed IPF diagnosis with certain lung function levels, and are either on a stable dose of standard IPF meds or not taking them.

Hefei, Anhui
NCT07682337Not yet recruiting· Phase 1
Testing a new drug in healthy men

This trial is testing a new drug called SCB0020160 in healthy adult men to see how safe it is and how the body processes it. You take the drug by mouth once or several times.

Adelaide, South Australia
NCT07719218Not yet recruiting· Phase 1
Safety study of inhaled drug ICF004 in healthy volunteers

This trial tests a new inhaled medication called ICF004 in healthy Chinese adults to see if it is safe and how the body processes it. You can join if you are generally healthy and between 18 and 50 years old.

Hear when a new Idiopathic Pulmonary Fibrosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.